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Abstract
Background: Unacknowledged inconsistencies in the reporting of clinical trials undermine the validity of the
results of the trials. Little is known about inconsistency in the reporting of academic clinical drug trials. Therefore,
we investigated the prevalence of consistency between protocols and published reports of academic clinical
drug trials.
Methods: A comparison was made between study protocols and their corresponding published reports. We assessed
the overall consistency, which was defined as the absence of discrepancy regarding study type (categorized as either
exploratory or confirmatory), primary objective, primary endpoint, and – for confirmatory trials only – hypothesis and
sample size calculation. We used logistic regression, χ2, and Fisher’s exact test.
Results: A total of 282 applications of academic clinical drug trials were submitted to the Danish Health and Medicines
Authority in 1999, 2001, and 2003, 95 of which fulfilled the eligibility criteria and had at least one corresponding
published report reporting data on trial subjects. Overall consistency was observed in 39 % of the trials (95 % CI: 29 to
49 %). Randomized controlled trials (RCTs) constituted 72 % (95 % CI: 63 to 81 %) of the sample, and 87 % (95 % CI: 80
to 94 %) of the trials were hospital based.
Conclusions: Overall consistency between protocols and their corresponding published reports was low. Motivators
for the inconsistencies are unknown but do not seem restricted to economic incentives.
Keywords: Clinical trial methodology, outcome-reporting bias, academic research, drug research, clinical trials,
published report
Background
The obligation to make results of clinical trials available
to the public is stated in the Declaration of Helsinki [1].
Furthermore, the validity of trial conclusions depends on
the use of stringent scientific methods as well as trans-
parency in the reporting of the results.
Unacknowledged discrepancies between protocols and
their corresponding published reports may undermine the
validity of the scientific effort [2], produce unfounded
conclusions, and lead to the unnecessary repetition of
trials with identical hypotheses and loss of generated
knowledge [3]. Particularly in the case of large long-
lasting clinical trials that are unlikely to be repeated, such
inconsistencies may jeopardize the risk-benefit ratio of the
investigational drug. At the regulatory level, changes made
during the conduct of a trial may invalidate the risk-
benefit assessment that lead to the initial approval of
the trial.
A recent Cochrane review [4] found that published
reports of randomized controlled clinical trials (RCTs)
frequently differ from their corresponding protocols or
trial registry data, for example, in the primary outcomes
[5–11] and sample size calculations [7, 8, 12, 13] for
interventions such as surgery, cosmetics, drugs, and
healthcare counseling. Discrepancies have also been
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found in the reporting of drug trials [10, 13–18]. Previ-
ous results mainly reflect the reporting of commercial
trials (range: 61 % to 100 % of study samples [7, 12, 14,
17, 19, 20]) or highly selected cohorts of publicly funded
phase III oncology trials and HIV RCTs [13, 15, 21].
However, all reviews indicated similar problems.
Discrepancies have also been found in published reports
of government-funded RCTs of various clinical special-
ties [8]. Whether these extend to non-commercial
drug trials, called academic drug trials, is unknown.
These trials are unrelated to drug companies or similar
economic influences and conducted in an array of clin-
ical specialties. We therefore investigated the prevalence
of the consistency between protocols and corresponding
published reports of Danish academic clinical drug trials.
Methods
The study sample consisted of all approved academic
clinical drug trial applications submitted to the Danish
Health and Medicines Authority in 1999, 2001, and
2003, which has been described previously [22]. The
trials were defined on the basis of the data as well as the
publication rights being the property of publicly
employed researchers and the absence of a pharmaceut-
ical company name on the first page of the protocol.
Trials with the sponsor living outside Denmark were
excluded, whereas 39 previously examined trials were
included [23].
Screening
For each trial, the corresponding published reports were
identified from May to September 2009 by a systematic
PubMed search. The follow-up time was at least 5 years.
The search terms were based on selected data from elec-
tronic files at the Danish Health and Medicines Authority:
sponsor’s name, protocol title, investigational medicinal
products, and a brief description, if available, of the study.
A published report was defined as any article report-
ing data on the trial subjects. PhD theses, conference
abstracts, reviews, and published reports not reporting
data on trial subjects were excluded as these are
either not indexed, not sufficiently detailed, or do not
contain trial results.
The names of the submitting sponsors were extracted
from all included trials, and contact information was
updated by searching Google or a registry of Danish
physicians. Contact to sponsor was made by e-mail or
letter for confirmation or correction of the identified
corresponding published report(s) or lack thereof. Two
reminders were sent in case of no response.
Data collection
Data were extracted from the protocols, including corres-
pondence and amendments, and from the corresponding
published reports. Pre-specified definitions of consistency
and discrepancy of the composite variables were devel-
oped and tested. Data were extracted by LB, and uncer-
tainties were discussed with LGP and TC. A continuous
decision log ensured reproducibility.
To avoid confusion, main outcomes denote those of
our study, whereas primary endpoints denote those of
the trials in the study sample. The main outcome was
overall consistency between protocols and their corre-
sponding published reports, which was a priori defined
as consistency on all of the following variables: study
type (exploratory/confirmatory), primary objective and
primary endpoint and – for pairs of confirmatory proto-
cols and corresponding confirmatory published reports
– also as consistency in the hypothesis and sample size
calculation. We also calculated the number of discrepan-
cies per trial and the prevalence of discrepancy regarding
each of the component variables.
If a published report showed discrepancy on a given
variable but provided transparency, by either clearly
stating the deviation from the protocol or referencing a
previous published report that describes the study in ac-
cordance with the protocol, the variable was considered
consistent.
The variables were defined as indicated below.
Discrepancy in the study type
We defined a confirmatory protocol/published report as
a study testing a pre-specified hypothesis, which was as-
sociated with a formal sample size calculation. Studies
with a primary confirmatory analysis and secondary
exploratory analyses were considered confirmatory. All
other studies were considered exploratory. A published
report was categorized as discrepant if the study type
differed from the study type derived from the protocol.
Discrepancy in the primary objective
The primary objective was defined as an objective
explicitly defined as such. If there was no explicitly
defined primary objective, the objective related to the
primary endpoint was considered primary. In the special
case of protocols consisting of more than one explicitly
defined primary objective, consistency was determined
as follows: 1) A published report stating the same or some
of the protocol-specified primary objectives was consid-
ered consistent with the protocol. 2) A published report
stating a non-protocol-specified primary objective was
considered discrepant regardless of the consistency of
other primary objectives. A published report only report-
ing secondary objectives and not stating the protocol-
specified primary objective was considered consistent with
the protocol only if a published report reporting or stating
the primary objective was referenced (that is, providing
transparency in the published report).
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Consistency in the primary endpoint
The primary endpoint(s) was (were) defined as the one
or two endpoints that were explicitly defined as primary.
If no primary endpoint was explicitly defined, the end-
point used in the sample size calculation was considered
as primary. If more than two endpoints were explicitly
defined as primary, the protocol was considered to have
no primary endpoints. In case of within-protocol or
within-published report inconsistency, only the primary
endpoint(s) substantiated in the body text was consid-
ered as primary. If one of two published report-specified
primary endpoints differed from the primary endpoint(s)
specified in the protocol, the published report was
considered discrepant.
Pairs of confirmative protocol/confirmative published
reports were also reviewed regarding discrepancy in the
hypothesis and sample size calculation.
Discrepancy in the hypothesis
Hypotheses from the protocol and published report were
compared. In the absence of an explicitly defined
hypothesis, we formulated a hypothesis based on the
sample size calculation as well as the rationale of the
study (for example, “A better than B”). In case of a
within-protocol inconsistency, the formulated hypothesis
was based on the sample size calculation. For example, a
protocol with a research question suited for an equivalence
or noninferiority trial, but statistically designed to demon-
strate superiority, was considered a superiority trial.
Discrepancy in the sample size calculation
The sample size calculation was considered discrepant if
either the calculated sample size or any of the available
components from the calculation differed between the
protocol and the published report. It was also considered
as a discrepancy if a sample size calculation was stated
in the protocol but missing from the published report.
The achieved sample size was not taken into account.
Data analysis and statistics
The sample size calculation was based on expected
frequencies of overall consistency of 40 or 62 % of the
trials. A sample size of 100 trials was chosen because the
inclusion of at least 92 trials would yield a standard
error of proportion (SEP)*z2α less than 0.1. Data were
registered in a Microsoft Access database with audit trail
and analyzed in SAS 9.2 using χ2 and Fischer’s exact tests
and logistic regression. P values < 0.05 were considered
statistically significant. Kappa values were analyzed with
GraphPad QuickCalcs (http://graphpad.com/quickcalcs).
Multivariate logistic regression was planned but not con-
ducted because only a few of the pre-specified variables
for the regression showed association with overall
consistency in 2 × 2 tables. We conducted post hoc
logistic regression analyses adjusted by the association
between published reports of the same protocol. This was
done by the use of a repeated measures statement and
with published reports as the unit of analysis.
Intra-rater agreement during data collection was
determined from the test-retest of five protocols and 16
corresponding published reports assessed within an
interval of 6 months. The variables were assumed inde-
pendent of each other. Study types, primary objectives,
and primary endpoints were extracted from 21 documents
(five protocols and 16 published reports). Hypotheses and
sample sizes were extracted from 10 documents (four
protocols and six published reports). Overall, 77 of
the 83 data points showed perfect agreement. The six
disagreements were distributed as follows: primary
endpoint (2/10), hypothesis (1/10), primary objective
(1/10), and sample size calculation (2/10). No disagree-
ments were found regarding trial type (exploratory/
confirmatory).
Results
A total of 282 applications of academic drug trials were
submitted to the Danish Health and Medicines Authority
in the period, 117 of which had more than one corre-
sponding published report and were included for
assessment (Fig. 1). During data collection, 22 trials
were excluded for the following reasons: investigator
not a resident in Denmark (n = 10), published report
did not correspond to the protocol (n = 10, in a few
cases, despite investigators verification), the published
report contained no data on trial subjects (n = 1), or
the year of application other than 1999, 2001, or
2003 (n = 1). The minimum follow-up time from
approval of protocol to screening publication rate was
282 academic clinical drug trials 
identified from the registry of the 
Danish Health and Medicines 
Authority
45 trials were excluded:
Application not approved, n = 23
File not found, n = 8
Sponsor not resident in Denmark, n = 12
Trial ongoing, n = 1
Year of submission other than 1999, 2001, or 2003, n = 1 
Survey cohort, n = 237 trials
95 published academic drug trials 
in the final sample
142 trials were excluded:
135 unpublished trials 
Trial not published according to sponsor, n = 89
No conclusive response and no PubMed finding, n = 35
Published report verified by sponsor, but did not 
correspond to protocol, n = 10
Published report did not contain data on trial subjects, n
= 1
7 trials not assessed
Paper file (protocol) missing, n = 4
Paper file not retrieved by mistake, n = 1
Fig. 1 Flow chart
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40 % (95/237). The final sample consisted of 95 ap-
proved clinical drug trials comprising 95 protocols
and 143 corresponding published reports (median:
one published report per trial, range: one to eight). Of
those, 42 (46 %) protocols described an exploratory trial,
whereas the remaining 53 (54 %) were confirmatory.
Characteristics of the exploratory and confirmatory
protocols are shown in Table 1, and characteristics of the
subgroup of controlled exploratory and confirmatory trials
in Table 2.
Most of the trials, 73 % (95 % CI: 63 to 81 %), were
randomized controlled trials (RCTs). The majority had
one or two pre-specified primary endpoints (77 %, 95 %
CI: 68 to 85) and pre-specified statistical methods (76 %,
95 % CI: 67 to 84 %). Most sponsors were employed in
hospitals within the Capital Region of Denmark (59 %,
95 % CI: 49 to 69 %) and were receiving, applying for, or
going to apply for grants from external sources (73 %,
95 % CI: 64 to 83 %).
Overall consistency was observed in 39 % of the trials
(95 % CI: 29 to 49 %, Table 3). The frequency was lower
among confirmatory trials compared to exploratory trials
(30 % versus 50 %). In comparison, overall consistency
was observed in 49 % of the published reports (95 % CI:
41 to 57 %). Confirmatory published reports were less
likely to show overall consistency compared to explora-
tory published reports (adjusted OR 0.37, 95 % CI: 0.17
to 0.83, Table 4).
The individual discrepancies are shown in Tables 3
and 4. The most prevalent was the primary endpoint
discrepancy (41 % of the trials, 95 % CI: 31 to 51 %).
Similarly, primary endpoint discrepancy was observed in
33 % of the published reports (95 % CI: 25 to 41 %). In
neither of the analyses did the occurrence of primary
Table 1 Protocol characteristics of academic clinical drug trials by type of study
Type of study
Total n (%) Exploratory n (%*) Confirmatory n (%*) P
Number of trials 95 42 53 -
Single/multicenter
Single center 71 (75 %) 31 (74 %) 40 (75 %) 0.85
Multicenter, national 16 (17 %) 8 (19 %) 8 (15 %) 0.78
Multicenter, international 8 (8 %) 3 (7 %) 5 (9 %) 1.00**
Sponsor’s affiliation
Hospital 83 (87 %) 40 (95 %) 43 (81 %) 0.06**
Medical practice 8 (8 %) 0 (0 %) 8 (15 %) 0.01**
University or other 4 (4 %) 2 (4 %) 2 (4 %) 1.00**
Good clinical practice (GCP)
Adherence to GCP 33 (35 %) 16/41 (39 %) 17/53 (32 %) 0.48
Missing (not stated in protocol or application) 1 (1 %) 1 (2 %) 0 (0 %) 1.00**
GCP monitoring 27 (28 %) 12 (29 %) 15 (28 %) 0.89
Control of compliance 29/51# (57 %) 8/15# (53 %) 21/36# (58 %) 0.86
Control groups
Control group 76 (80 %) 26 (62 %) 50 (94 %) <0.001
Control group, historical 0 (0 %) 0 (0 %) 0 (0 %) -
Endpoints, power and sample size
Statement of endpoints 95 (100 %) 42 (100 %) 53 (100 %) -
Statement of one to two primary endpoints 73 (77 %) 23 (55 %) 50 (94 %) <0.001**
Statement of sample size calculation 65 (68 %) 12 (29 %) 53 (100 %) <0.001**
Statement of statistical methods 72 (76 %) 32 (76 %) 40 (75 %) 0.94
Funding
External funding granted or wanted 61/83 (73 %) 27/38 (71 %) 34/45 (76 %) 0.64
Missing (not stated in protocol or application) 12 (13 %) 4 (10 %) 8 (15 %) 0.54**
*Prevalence in each subgroup, for example, a control group is present in 26 of 42 exploratory trials (62 %)
**Fischer’s exact test due to fewer than five observations in a single cell
#n = 51, because compliance was considered “not relevant” in 27 exploratory and in 17 confirmatory trials
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endpoint discrepancy seem to be associated with the
study type (exploratory or confirmatory).
Of the 58 trials with at least one discrepancy, 23 trials
were associated with one discrepancy, and 35 trials with two
or more discrepancies. Half of the published reports (73/
143) showed discrepancy. Of these 73 published reports,
35 had one discrepancy, 31 had two, and seven had three
discrepancies. None had more than three discrepancies.
Agreement on the published report status between the
survey and the literature search was estimated from the
183 trials with a conclusive survey response. The Kappa
statistic κ = 0.782 indicated good agreement (95 % CI:
0.692 to 0.872, agreement for 91 % of the trials).
Discussion
In this review and follow-up of academic drug trials in
Denmark, we found overall consistency between the
approved protocol and resulting published reports in
39 % (95 % CI: 51 to 70 %) of the trials. The assessment
of overall consistency included the following composite
variables: primary objective, primary endpoint, type of
study, hypothesis, and reporting of power calculation.
The most prevalent was discrepancy on the primary
endpoint (41 %), but the type of study and primary ob-
jective differed frequently as well, among 23 % and 20 %
of the trials, respectively. The publication rate of 40 % is
comparable to our findings in a similar cohort (33 %)
[22].
Few studies of the reporting of clinical trials have been
conducted on academic drug trials [13, 15, 21] or even
academic drug/non-drug trials [9]. To our knowledge,
this is the first investigation of protocol-published report
consistency in academic drug trials across medical
specialties. To provide data as solid as possible, we used
predefined eligibility criteria based on the ownership of
trial data and publication rights rather than the source(s)
of funding, we included RCTs and non-RCTs from all
medical specialties, and we categorized the trials by the
nature of their research question as exploratory or
confirmatory. Furthermore, we constructed a composite
outcome, overall consistency, which took into account
some of the differences between exploratory and confirma-
tory trials. The bias from selection of trials was minimized
because we had access to all trials approved in Denmark.
Previous studies on the reporting of drug trials [10, 13–18]
primarily included commercial trials. However, our study
demonstrates that drug trials that cannot be assumed to
involve heavy economic interests also have a similar lack
of consistency. This is in agreement with the findings of
Chan et al. [8] in a cohort of government-funded drug/
Table 2 Protocol characteristics of academic clinical drug trials by type of study, continued
Type of study
Total n (%) Exploratory n (%*) Confirmatory n (%*) P
Number of controlled trials 76 26 50 -
Design
Parallel 38 (50 %) 11 (42 %) 27 (54 %) 0.33
Cross-over 37 (49 %) 14 (54 %) 23 (46 %) 0.52
Other 1 (1 %) 1 (4 %) 0 (0 %) 0.34**
Blinding 57 (75 %) 16 (62 %) 41 (82 %) 0.051
Randomization 69 (91 %) 20 (77 %) 49 (98 %) 0.006
*Prevalence in each subgroup; for example, a parallel design was used in 27 of the confirmatory trials (54 %)
Table 3 Overall consistency and discrepancy between protocols and corresponding published reports of academic drug trials by
protocol-derived type of study, N = 95 protocols
All trials Exploratory trials Confirmatory trials
n % (95 % CI) n % (95 % CI)* n % (95 % CI)*
Number of trials 95 42 53
Overall consistency 37 39 % (29 to 49 %) 21 50 % (35 to 65 %) 16 30 % (18 to 43 %)
Individual discrepancies
Type of study 22 23 % (15 to 32 %) 6 14 % (4 to 25 %) 16 30 % (18 to 43 %)
Primary objective 19 20 % (12 to 28 %) 12 29 % (15 to 42 %) 7 13 % (4 to 22 %)
Primary endpoint 39 41 % (31 to 51 %) 16 38 % (23 to 53 %) 23 43 % (30 to 57 %)
Hypothesis - 17 - - - 5/37◊ 14 % (2 to 25 %)
Sample size calculation - - - - 17/37◊ 46 % (30 to 62 %)
*Prevalence in each subgroup; for example, 21 of 42 exploratory trials (50 %) showed overall consistency
◊Based on the subgroup of 37 trials with a confirmatory protocol and more than one confirmatory published report
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non-drug RCTs. The observed discrepancies are of such
a magnitude that we believe our results represent a real
problem in the reporting of academic clinical drug tri-
als. Previously, the focus has primarily been on RCTs,
which require a well-defined design for the testing of
specific hypotheses [24]. However, control groups and
randomization are also used in exploratory trials. In our
study sample, 20/69 (29 %) of the randomized trials
were categorized as exploratory, whereas confirmatory
studies constituted 4/26 (15 %) of the nonrandomized
trials. This suggests that limitations apply to the use of
randomization as an inclusion criterion in the evalu-
ation of methodological quality from a perspective of
evidence-based medicine.
To ensure consistency and reproducibility from using a
single assessor (LB), we implemented quality assurance
and control measures, such as the development and test
of clear definitions of consistency and discrepancy, the
keeping of a decision log during data collection, and the
test-retest of the assessment of the outcome variables.
The intra-rater agreement was assessed and reported
using the pre-specified unit of measurement and analysis
plan. Alternatively, intra-rater agreement could have been
analyzed using protocols as the unit of measurement. This
would have required a larger sample for the assessment
but would also have provided a better estimate.
In a few cases, difficulties in collecting data from the
protocols was due to the contradictory definitions of the
primary endpoint, which points to other problems in the
writing of the protocol as well as in the approval proce-
dures of the competent authorities. Since this was not
predefined in our study, we did not investigate it further.
Discrepancies within a published report or between
published reports of the same trial may be associated.
The adjusted and unadjusted post-hoc logistic regres-
sions at the published report level did not change our
primary results. Discrepancies were frequent in pub-
lished reports regardless of the study type of the under-
lying protocol (exploratory/confirmatory) and the study
type derived from the published report. We found a
discrepancy in half of the 143 published reports, each
carrying a risk of the study results being misinterpreted
due to inadequate or misleading information. We did
not assess whether the discrepancies were associated
with the direction of the trial results. Nevertheless, the
risk of bias exists, which may be forwarded to future
research and clinical decisions.
We have not found previous reports on the transform-
ation of exploratory protocols to confirmatory published
reports, a topic that is highly important because the
study type implies certain strengths and limitations to
the interpretation of the study results [25, 26]. Such
discrepancy in 14 % and 30 % of exploratory and confirma-
tory trials is problematic. Similarly, the discrepancy in
primary endpoints in 41 % of academic clinical drug trials is
critical but consistent with earlier findings (33 % to 62 % of
RCTs [7, 8, 10]). Discrepancy regarding the primary object-
ive was less frequent but was associated with discrepancy of
the primary endpoint (P < 0.0001, χ2, data not shown).
Published reports neither stating nor referencing the
protocol-specified (or any other) sample size calculation,
and therefore defined as exploratory, were found in 46 %
of the confirmatory trials; this figure is comparable to
the 53 % reported by Chan [20] and the 59 % by Mhaskar
[15]. The transparent reporting of the sample size calcula-
tion allows the reader to assess the power and pre-
specified relevant clinical benefit of the study [27].
We studied a cohort of trials approved until 2003.
Since then, the Clinical Trials Directive has been intro-
duced, and the International Committee of Medical
Journal Editors (ICMJE) has facilitated transparency in
the reporting of research by requiring clinical trials to be
registered in a publicly available database [28]. As of
2011, information on all clinical drug trials approved
since May 2004 by the European medicines authorities is
publicly available [29, 30]. The information is limited
but is directly uploaded by the authorities at the time of
approval, thus serving to reduce the problem of retro-
spective registration. Such resources provide a valuable
tool to journal editors and reviewers if kept up to date
with accurate information and if used actively during jour-
nal review. However, the occurrence of missing or unclear
Table 4 Overall consistency and discrepancy between protocols and corresponding published reports by published report-derived
type of study, N = 143 published reports
Exploratory published reports N = 96 Confirmatory published reports N = 47 Crude OR Adjusted OR#
n % (95 % CI) n % (95 % CI) OR (95 % CI) OR (95 % CI)
Overall consistency 53 55 % (45 to 65 %) 17 36 % (22 to 50 %) 0.46 (0.22 to 0.94) 0.37 (0.17 to 0.83)
Individual discrepancies
Type of study 17 18 % (10 to 25 %) 6 13 % (3 to 22 %) 0.68 (0.25 to 1.87) 0.64 (0.21 to 1.48)
Primary objective 21 22 % (14 to 30 %) 5 11 % (2 to 19 %) 0.43 (0.15 to 1.21) 0.56 (0.11 to 2.80)
Primary endpoint 34 35 % (26 to 45 %) 13 28 % (15 to 40 %) 0.70 (0.32 to 1.50) 0.68 (0.31 to 1.48)
*Prevalence in each subgroup; for example, 53 of 96 exploratory published reports (55 %) showed overall consistency
#Adjusted for the association between published reports of the same trial (median: one published report per trial, range: one to eight)
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registry data [31, 32] and many trials being registered
retrospectively [33] substantiates the continued use of
protocols as the primary source of trial characteristics
[34]. Evidence of discrepancies, even between trial regis-
tries and published reports [4], indicate that a dedicated
effort is still required by the researchers as well as the
journal editors and reviewers to promote transparency in
the reporting of clinical research. Studies assessing the
consistency in the reporting of clinical trials should be
conducted at regular intervals to ensure a continued im-
provement in the reporting.
In Denmark, academic trials constitute a third of clinical
drug trials [22], with a high proportion of confirmatory
trials providing a considerable contribution to the
accumulation of clinical evidence. The impact on clinical
practice of academic versus commercial trials is unknown,
but differences may exist. Probably, commercial trials have
their main impact on the registration of drugs, whereas
academic drug trials probably have mostly other impacts.
The reasons for discrepancy between protocols and
published reports are unknown and may be complex,
but it seems there are other motivators than economic
driving forces. Previous studies point to reasons such as
a lack of clinical importance, lack of statistical signifi-
cance, and unawareness of the consequences of not
reporting all outcomes and protocol changes [8, 35].
Conclusion
In this study, we predefined overall consistency between
protocols and published reports as the primary focus and
found it to be low for academic clinical drug trials. The
discrepancies pose an invisible threat to the validity of trial
conclusions. These results indicate a general need for im-
proving the consistency between protocols and the result-
ing published reports, particularly regarding the definition
of the primary endpoint and of the trial as exploratory or
confirmatory. Further studies are needed to assess im-
provements in the reporting of clinical trials over time.
Abbreviations
CI: confidence interval; GCP: good clinical practice; HIV: human immunodeficiency
virus; ICMJE: International Committee of Medical Journal Editors; OR: odds ratio;
RCT: randomized controlled clinical trial; SEP: standard error of proportion.
Competing interests
LB was employed by the GCP unit at Copenhagen University Hospital,
Copenhagen, Denmark, and the Danish Health and Medicines Authority,
Copenhagen, Denmark, during the conduct and reporting of this study. LB is
currently employed by Novo Nordisk A/S. Novo Nordisk A/S was not
involved in the study or the reporting of it.
Authors’ contributions
LB and HEP were responsible for the study concept. LB, KD, KFB, TC, LGP,
and HEP designed the study. LB, LGP (supervision), and TC (supervision)
were responsible for data collection. LB, KD, TC, LGP, KFB, and HEP were
responsible for the analysis and interpretation. LB drafted the
manuscript. KD, TC, LGP, KFB, and HEP critically revised the manuscript.
LB and KD were responsible for the fundraising. All authors read and
approved the final manuscript.
Acknowledgements
The study was funded by the GCP Unit at Copenhagen University Hospital,
Danish Health and Medicines Authority, Laboratory of Clinical Pharmacology
at Rigshospitalet, Faculty of Health Sciences at University of Copenhagen,
and the Lundbeck Foundation. The Lundbeck Foundation had no influence
on the design and conduct of the study; the collection, management,
analysis, and interpretation of the data; or the preparation, review, and
approval of the manuscript.
LB had full access to all data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis.
Author details
1The GCP Unit at Copenhagen University Hospital, Bispebjerg University
Hospital, Copenhagen, Denmark. 2Medicines Development & Clinical Trials,
Danish Health and Medicines Authority, Copenhagen, Denmark.
3Department of Clinical Pharmacology, Bispebjerg University Hospital,
Copenhagen, Denmark. 4Laboratory of Clinical Pharmacology, Rigshospitalet,
Denmark. 5Faculty of Health and Medical Sciences, University of
Copenhagen, Copenhagen, Denmark. 6Present affiliation: Novo Nordisk A/S,
Copenhagen, Denmark. 7Present affiliation: Division of Pharmacovigilance
and Medical Devices, Danish Health and Medicines Authority, Copenhagen,
Denmark. 8Present affiliation: Faculty of Health Sciences, University of
Copenhagen, Copenhagen, Denmark. 9Nybro Vænge 3, Kongens Lyngby
DK-2800, Denmark.
Received: 28 September 2015 Accepted: 20 January 2016
References
1. World Medical Association. WMA Declaration of Helsinki - Ethical principles
for medical research involving human subjects. www wma net/en/
30publications/10policies/b3/index html. [serial online] 2008;
Accessed 12 May 2013.
2. Chan AW, Upshur R, Singh JA, Ghersi D, Chapuis F, Altman DG. Research
protocols: waiving confidentiality for the greater good. BMJ. 2006;332:1086–9.
3. Dickersin K CI. Recognising, investigating and dealing with incomplete and
biased reporting of clinical research: from Francis Bacon to the World
Health Organisation. www jameslindlibrary org/illustrating/articles/
recognising-investigating-and-dealing-with-incomplete-and-biase. [serial
online] 2013; Available from: The James Lind Library. Accessed 13 May 2013.
4. Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR.
Comparison of protocols and registry entries to published reports for
randomised controlled trials. Cochrane Database Syst Rev. 2011;1:MR000031.
5. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials:
analysis of trial protocols accepted by The Lancet. Lancet. 2008;372:201.
6. Blumle A, Antes G, Schumacher M, Just H, von Elm E. Clinical research
projects at a German medical faculty: follow-up from ethical approval to
publication and citation by others. J Med Ethics. 2008;34:e20.
7. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical
evidence for selective reporting of outcomes in randomized trials:
comparison of protocols to published articles. JAMA. 2004;291:2457–65.
8. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in
randomized trials funded by the Canadian Institutes of Health Research.
CMAJ. 2004;171:735–40.
9. Hahn S, Williamson PR, Hutton JL. Investigation of within-study selective
reporting in clinical research: follow-up of applications submitted to a local
research ethics committee. J Eval Clin Pract. 2002;8:353–9.
10. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome Reporting in
Industry-Sponsored Trials of Gabapentin for Off-Label Use. N Engl J
Med. 2009;361:1963–71.
11. von Elm E, Rollin A, Blumle A, Huwiler K, Witschi M, Egger M. Publication
and non-publication of clinical trials: longitudinal study of applications
submitted to a research ethics committee. Swiss Med Wkly.
2008;138:197–203.
12. Pich J, Carne X, Arnaiz JA, Gomez B, Trilla A, Rodes J. Role of a research
ethics committee in follow-up and publication of results. Lancet.
2003;361:1015–6.
13. Soares HP, Daniels S, Kumar A, et al. Bad reporting does not mean bad
methods for randomised trials: observational study of randomised
controlled trials performed by the Radiation Therapy Oncology Group.
BMJ. 2004;328:22–4.
Berendt et al. Trials  (2016) 17:100 Page 7 of 8
14. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased
medicine–selective reporting from studies sponsored by pharmaceutical
industry: review of studies in new drug applications. BMJ. 2003;326:1171–3.
15. Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published
methodological quality of randomized controlled trials does not reflect the
actual quality assessed in protocols. J Clin Epidemiol. 2012;65:602–9.
16. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective
publication of antidepressant trials and its influence on apparent efficacy.
N Engl J Med. 2008;358:252–60.
17. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the
Food and Drug Administration: review of publication and presentation.
PLoS Med. 2008;5:e217.
18. von Elm E, Rollin A, Blumle A, Senessie C, Low N, Egger M. Selective
reporting of outcomes of drug trials? Comparison of study protocols and
published articles [abstract]. XIV Cochrane Colloquium; 2006 October 23-26;
Dublin, Ireland 2006; 47.
19. Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC.
Comparison of descriptions of allocation concealment in trial protocols and
the published reports: cohort study. BMJ. 2005;330:1049.
20. Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG.
Discrepancies in sample size calculations and data analyses reported in
randomised trials: comparison of publications with protocols. BMJ.
2008;337:a2299.
21. Gandhi M, Ameli N, Bacchetti P, et al. Eligibility criteria for HIV clinical trials
and generalizability of results: the gap between published reports and
study protocols. AIDS. 2005;19:1885–96.
22. Berendt L, Hakansson C, Bach KF, et al. Effect of European Clinical Trials
Directive on academic drug trials in Denmark: retrospective study of
applications to the Danish Medicines Agency 1993-2006. BMJ. 2008;336:33–5.
23. Berendt L, Hakansson C, Bach KF, et al. Methodological characteristics of
academic clinical drug trials–a retrospective cohort study of applications to the
Danish Medicines Agency 1993-2005. Br J Clin Pharmacol. 2010;70:729–35.
24. Eccles M, Freemantle N, Mason J. North of England evidence based
guidelines development project: methods of developing guidelines for
efficient drug use in primary care. BMJ. 1998;316:1232–5.
25. Vandenbroucke JP. Observational research, randomised trials, and two views
of medical science. PLoS Med. 2008;5:e67.
26. Sheiner LB. Learning versus confirming in clinical drug development. Clin
Pharmacol Ther. 1997;61:275–91.
27. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. PLoS Med.
2010;7:e1000251.
28. International Committee of Medical Journal Editors. Uniform Requirements
for Manuscripts Submitted to Biomedical Journals: Publishing and Editorial
Issues Related to Publication in Biomedical Journals: Obligation to Register
Clinical Trials. www icmje org/. [serial online] 2012; Accessed 13 May 2013.
29. European Medicines Agency. EU Clinical Trials Register. www
clinicaltrialsregister eu [serial online] 2013; Accessed 12 August 2013.
30. WHO. International Clinical Trials Registry Platform (ICTRP). ww who int/
ictrp/en/. [serial online] 2013; Accessed 12 August 2013.
31. Moja L, Moschetti I, Nurbhai M, et al. Compliance of clinical trial registries
with the World Health Organization minimum data set: a survey. Trials.
2009;10:56.
32. Huic M, Marusic M, Marusic A. Completeness and Changes in Registered
Data and Reporting Bias of Randomized Controlled Trials in ICMJE Journals
after Trial Registration Policy. PLoS One. 2011;6:e25258.
33. Faure H, Hrynaszkiewicz I. The ISRCTN Register: achievements and
challenges 8 years on. J Evid Based Med. 2011;4:188–92.
34. Reveiz L, Chan AW, Krleza-Jeric K, et al. Reporting of Methodologic
Information on Trial Registries for Quality Assessment: A Study of Trial
Records Retrieved from the WHO Search Portal. PLoS One. 2010;5:e12484.
35. Smyth RM, Kirkham JJ, Jacoby A, Altman DG, Gamble C, Williamson PR.
Frequency and reasons for outcome reporting bias in clinical trials:
interviews with trialists. BMJ. 2011;342:c7153.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Berendt et al. Trials  (2016) 17:100 Page 8 of 8
